Hikari Tsushin Inc. Acquires 51,937 Shares of Zoetis Inc. $ZTS

Hikari Tsushin Inc. lifted its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 22.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 285,554 shares of the company’s stock after purchasing an additional 51,937 shares during the quarter. Zoetis comprises about 1.3% of Hikari Tsushin Inc.’s holdings, making the stock its 11th biggest holding. Hikari Tsushin Inc.’s holdings in Zoetis were worth $19,940,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. BlackRock Inc. increased its position in Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares in the last quarter. State Street Corp lifted its position in shares of Zoetis by 1.8% during the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after purchasing an additional 343,322 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Zoetis by 5.8% during the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after purchasing an additional 319,709 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Zoetis by 7.3% during the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after purchasing an additional 327,313 shares during the last quarter. Finally, Van ECK Associates Corp grew its stake in shares of Zoetis by 7.7% during the second quarter. Van ECK Associates Corp now owns 4,252,140 shares of the company’s stock valued at $305,559,000 after purchasing an additional 303,395 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 2.1%

NYSE ZTS opened at $79.09 on Friday. The company has a market capitalization of $32.14 billion, a PE ratio of 13.45, a P/E/G ratio of 1.22 and a beta of 0.67. The stock has a 50-day simple moving average of $77.16 and a 200 day simple moving average of $90.55. The company has a current ratio of 2.35, a quick ratio of 1.40 and a debt-to-equity ratio of 2.51. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $132.49.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. Zoetis’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.70 EPS. Research analysts forecast that Zoetis Inc. will post 6.29 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is currently 36.05%.

Top Zoetis Stories

Here are a few of the latest stories about ZTS:

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 29th. Piper Sandler reduced their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. JPMorgan Chase & Co. decreased their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. BNP Paribas Exane decreased their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Finally, BTIG Research dropped coverage on Zoetis in a research note on Friday, October 30th. They issued a “buy” rating and a $200.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average price target of $101.25.

View Our Latest Report on Zoetis

Zoetis Profile

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.